TY - JOUR
T1 - Association of exposure to Toxoplasma gondii, Epstein-Barr Virus, Herpes Simplex virus Type 1 and Cytomegalovirus with new-onset depressive and anxiety disorders
T2 - An 11-year follow-up study
AU - Markkula, Niina
AU - Lindgren, Maija
AU - Yolken, Robert H.
AU - Suvisaari, Jaana
N1 - Funding Information:
This work was supported by Stanley Medical Research Institute, Juho Vainio Foundation (ML), Yrjö Jahnsson Foundation (ML, grant number 6979) and Helsinki University Competitive Research Funding (NM). The funding sources had no role in the study design, in the collection, analysis and interpretation of data, in the writing of the report, or the decision to submit the article for publication.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2020/7
Y1 - 2020/7
N2 - Background: Some prevalent infections have been associated with common mental disorders, but there are few longitudinal studies, and results are inconsistent. We aimed to assess whether serological evidence of exposure to Toxoplasma gondii (T. gondii), Epstein-Barr Virus (EBV), Herpes Simplex virus Type 1 (HSV-1) and Cytomegalovirus (CMV) predict development of new-onset depressive and anxiety disorders. Methods: In a nationally representative sample of the Finnish adult population aged 30 and over (BRIF8901, n = 8028), IgG antibodies for T. gondii, EBV, HSV-1 and CMV were measured in plasma samples. The population was followed up for 11 years and new-onset depressive and anxiety disorders were diagnosed with the Composite International Diagnostic Interview. Associations were analysed controlling for sex, age, educational level, region of residence and marital status, and in separate analyses also for C-reactive protein level. Results: Seropositivity and serointensity of the four infectious agents were not associated with an increased risk of new-onset depressive or anxiety disorders. Seropositivity for CMV at baseline was associated with a lower risk of new-onset generalized anxiety disorder (adjusted OR 0.43, 95% CI 0.22–0.86 for CMV positive persons). Conclusion: The results of this large, nationally representative longitudinal study suggest that common viral infections are not significant risk factors for common mental disorders. The association of CMV with a lower risk of generalized anxiety disorder warrants further investigation.
AB - Background: Some prevalent infections have been associated with common mental disorders, but there are few longitudinal studies, and results are inconsistent. We aimed to assess whether serological evidence of exposure to Toxoplasma gondii (T. gondii), Epstein-Barr Virus (EBV), Herpes Simplex virus Type 1 (HSV-1) and Cytomegalovirus (CMV) predict development of new-onset depressive and anxiety disorders. Methods: In a nationally representative sample of the Finnish adult population aged 30 and over (BRIF8901, n = 8028), IgG antibodies for T. gondii, EBV, HSV-1 and CMV were measured in plasma samples. The population was followed up for 11 years and new-onset depressive and anxiety disorders were diagnosed with the Composite International Diagnostic Interview. Associations were analysed controlling for sex, age, educational level, region of residence and marital status, and in separate analyses also for C-reactive protein level. Results: Seropositivity and serointensity of the four infectious agents were not associated with an increased risk of new-onset depressive or anxiety disorders. Seropositivity for CMV at baseline was associated with a lower risk of new-onset generalized anxiety disorder (adjusted OR 0.43, 95% CI 0.22–0.86 for CMV positive persons). Conclusion: The results of this large, nationally representative longitudinal study suggest that common viral infections are not significant risk factors for common mental disorders. The association of CMV with a lower risk of generalized anxiety disorder warrants further investigation.
UR - http://www.scopus.com/inward/record.url?scp=85076558566&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076558566&partnerID=8YFLogxK
U2 - 10.1016/j.bbi.2019.12.001
DO - 10.1016/j.bbi.2019.12.001
M3 - Article
C2 - 31809804
AN - SCOPUS:85076558566
SN - 0889-1591
VL - 87
SP - 238
EP - 242
JO - Brain, Behavior, and Immunity
JF - Brain, Behavior, and Immunity
ER -